Physician profile
James S Scott
NPI 1134115637
$307,018.90
in general payments reported to CMS, 2019-2025
29 companies · $6,809 in 2025
The $6,809 reported for 2025 was more than what 93% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $80K · 2021: $88K · 2022: $37K · 2023: $5,771 · 2024: $2,263 · 2025: $6,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Education: $2,000 · Travel and Lodging: $1,540 · Consulting Fee: $1,000 · Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Education | $2,000.00 |
| Travel and Lodging | $1,539.91 |
| Consulting Fee | $1,000.00 |
| Food and Beverage | $802.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $302,915.04 | 2019-2025 | Da Vinci Surgical System |
| Ethicon INC. | $1,698.10 | 2022 | |
| Endogastric Solutions, INC | $1,113.83 | 2021 | |
| Abbvie INC. | $297.66 | 2021-2025 | Creon, Natrelle Saline-Filled Breast Implants |
| Tela Bio, INC. | $127.11 | 2019-2022 | |
| Covidien LP | $112.36 | 2019 | |
| Apollo Endosurgery US INC | $111.79 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $103.96 | 2019 | |
| Ethicon US, LLC | $93.23 | 2021-2025 | Echelon; Endopath |
| Takeda Pharmaceuticals U.S.A., INC. | $57.74 | 2020-2024 | Gattex |
| Kerecis Limited | $41.39 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $27.30 | 2023 | Puraply |
| Acera Surgical, INC. | $26.74 | 2025 | Restrata Wound Matrix |
| Medtronic, INC. | $26.70 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $25.97 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.66 | 2024 | Voquezna |
| Becton, Dickinson and Company | $22.57 | 2022 | |
| Ambu INC. | $20.06 | 2021 | |
| Novo Nordisk INC | $19.87 | 2024 | Wegovy |
| Polynovo North America LLC | $19.80 | 2024 | Novosorb Btm |
| Vertex Pharmaceuticals Incorporated | $19.59 | 2025 | |
| Standard Bariatrics, INC. | $17.65 | 2022 | |
| Boston Scientific Corporation | $16.14 | 2025 | Apollo 2-0 Polypropylene Endobariatric Suture |
| Lifenet Health | $16.06 | 2023 | |
| Olympus America INC. | $15.17 | 2025 | 4k Cable 3.0m |
| Mesh Suture INC | $14.18 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $13.99 | 2023 | Imcivree |
| Lilly USA, LLC | $11.69 | 2020 | |
| Merit Medical Systems INC | $8.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.